An ongoing dialogue on HIV/AIDS, infectious diseases,
October 29th, 2011
Will An Antiretroviral Patch Help Adherence? Doubtful …
This little nugget came up recently, found by our Journal Watch Executive Editor:
Preliminary research suggests that a patch could deliver an AIDS drug to patients … The researchers successfully used transdermal patches to administer 96 percent of an AIDS drug to simulated skin over a week. “Still, the important limitation of pills, regardless of how few there are or even how minimal the side effects, is adherence,” Johnston [the investigator] noted. Research has shown that many patients, if not most, don’t take their pills all the time.
Setting aside for a moment the fact that most patients actually do take their medications just fine, thank you — and that this particular transdermal HIV drug delivery system hasn’t even been tested on animals, let alone humans — I have always wondered about the assumption that novel drug delivery systems would improve adherence.
Seems to me that the major problem with non-adherent patients isn’t that they can’t take pills.
It’s that they won’t take them.
And I strongly suspect that most would make the same choice when it comes to putting on a patch every day (or even every week).
Categories: HIV, Patient Care, Research
Tags: antiretroviral therapy, drug delivery systems, HIV
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
2 Responses to “Will An Antiretroviral Patch Help Adherence? Doubtful …”

Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
Most Popular Posts
Sorry. No data so far.
-
From the Blog — Most Recent Articles
- Farewell to This Blog — and Hello to NEJM Voices March 2, 2026
- Some Ruminations on CROI — Still the Best HIV Meeting February 26, 2026
- Two Things Can Be True: The FDA Process Was Inconsistent, and the mRNA Vaccine Data Were Disappointing February 17, 2026
- Sometimes You Just Need to Get Input from a Real Human Being February 12, 2026
- Mystifying Abbreviations — Infectious Diseases Edition February 4, 2026
FROM NEJM — Recent Infectious Disease Articles- Case 21-2026: A 28-Year-Old Man with Headache and Vision Loss in the Right Eye July 23, 2026A 28-year-old man was admitted to the hospital because of monocular vision loss. Examination showed optic disk edema, and imaging revealed liver lesions and lymphadenopathy. A diagnosis was made.
- Klebsiella Brain Abscess and Evolution of Heterovirulence in the Urinary Tract July 23, 2026In a patient with a staghorn calculus, chronic urinary tract infection with Klebsiella pneumoniae enabled within-patient evolution of virulence properties that facilitated dissemination of infection, leading to a brain abscess.
- The Best of Both Worlds — Using Clinical Trial and Observational Data to Evaluate Vaccine Protection July 23, 2026Well-designed observational studies are critical to advancing understanding of the effects of vaccines. But they are often dismissed as lacking the methodologic rigor necessary to inform policymaking.
- Neurocysticercosis July 23, 2026A 52-year-old woman presented with a 4-month history of headache and visual hallucinations. MRI of the brain showed cystic lesions containing bright nodules.
- National Elimination of Hepatitis C — The Case for Starting in Prisons and Jails July 23, 2026The United States could take meaningful steps toward eliminating hepatitis C by broadly testing and treating people who are involved in the criminal legal system.
- Case 21-2026: A 28-Year-Old Man with Headache and Vision Loss in the Right Eye July 23, 2026
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster

Perhaps most patients in that Baltimore, MD study take their medications just fine… what about those at high risk for nonadherence? Putting on a patch once a week (perhaps supervised during a home visit by a health worker) could be a real improvement over twice-daily pills for some PLH whom I have encountered in a developing country setting. It could certainly be easier for those with a variable sleep or work schedule. I think it would be a simpler option for me if I were on ART.
Hi Amy,
Agree it might be handy … for those who agree to do it!
I also think that Baltimore study is pretty representative of a very challenging group of patients — here’s my review of it:
http://cid.oxfordjournals.org/content/53/6/605.full
My rough estimate is that around 10-20% of HIV patients don’t take their meds, but they loom very large in our minds since we spend so much time agonizing over them!
Paul